PROGRESS IN CANCER RESEARCH has depended on the continual development of increasingly relevant preclinical models of human cancers, ranging from human and animal cell lines grown in vitro to genetically engineered animal models of cancer. There remains a high failure rate, however, of new cancer treatments that are found to be successful in preclinical trials. This is attributed to the inability of many preclinical models to recreate the heterogeneity seen in human patient tumors. 1 Recently, patient-derived xenograft (PDX) models have gained popularity in cancer research due to their ability to better recapitulate the heterogeneity of human tumors. [2] [3] [4] [5] Furthermore, PDX models have been shown to predict clinical responses to chemotherapeutic drugs more accurately than other platforms, which centralizes the role of PDX models in a new generation of personalized cancer therapy. 1, 3, 6 One major limitation of PDX models is the need for operative resection of a patient's cancer tissue in order to generate xenografts. Many cancer patients do not receive any operative resection of tumor tissue, and operative rates vary greatly by the type of cancer. In an National Health Service study, operative resection rates ranged from 80% of uterine and female breast cancer patients to less than 10% of patients with cancer of the liver, bladder, prostate, lung, and pancreas. 7 Therefore, we hypothesized that new PDX tumors could be established from small volumes of tumor tissue, such as that obtained during fine needle aspirates (FNAs) or core needle biopsies obtained during diagnostic workup. Recently, Allaway et al demonstrated that it was feasible to engraft FNA samples of pancreatic adenocarcinoma obtained during endoscopic ultrasound-directed fine needle aspiration procedures. We also confirmed these findings in pancreatic adenocarcinoma and explored the possibility of FNA xenografts in urothelial, lung, and melanoma specimens.
MATERIALS AND METHODS
Patient-derived tissue and ethics statement. Operatively resected tumor specimens were obtained from patients with pancreatic carcinomas, non-small cell lung carcinomas, melanomas, and urothelial cell carcinomas of the bladder. All operatively resected tumors were collected after written patient consent and in accordance with the institutional review board (IRB)-approved protocols of the University of Texas M. D. Anderson Cancer Center (protocols: Pancreatic Cancer LAB07-0854, Lung LAB10-0704, Bladder LAB08-0179, and Melanoma LAB07-0875).
All operatively resected specimens were accepted as they became available, and no samples were excluded based on pretreatment status. All animals were housed and maintained under guidelines established by the American Association of Laboratory and Animal Care, and animal experiments were performed in accordance with the National Institutes of Health Animal Care and Use Committee (ACUC) guidelines (protocol 09-07-10131) after The University of Texas M. D. Anderson Cancer Center IRB approval.
Establishment of patient-derived cancer xenografts from tumor fragments and biopsy samples. The establishment of direct heterotopic xenograft tumors in NOD/SCID mice has been described in detail previously. 5 After gross determination of viable tumor by the attending pathologist, specimens were resected and kept in ice cold cell culture media composed of RPMI 1640 supplemented with 10% fetal bovine serum (Hyclone Laboratories, Waltham, MA) and 2% penicillin/streptomycin (Sigma-Aldrich).
The time from operative resection to placement of samples in cold media (warm ischemia time) was under 30 minutes, and the time in cold media was under one hour. All NOD/SCID mice were purchased from the National Cancer Institute (Bethesda, Maryland); 4-to 6-week-old NOD/SCID mice were anesthetized with inhaled isoflurane. Patient tumors in cold media were minced into fragments 1-2 mm 3 in volume. In order to simulate a clinical biopsy, each tumor fragment was biopsied by passing a 22-gauge needle 3 times through the tissue, while gently aspirating with a 1-cc syringe. Subsequently, liquid matrigel (BD Biosciences, San Jose, CA) was aspirated with the syringe to make a total volume of approximately 100 mL.
The syringe contents were then injected subcutaneously in the flank of the NOD/SCID mouse. The same tumor fragment that was biopsied was then implanted subcutaneously in the contralateral flank of the same mouse as a control, along with approximately 100 mL of cell culture media and liquid matrigel (Fig 1) . Two to 5 NOD/SCID mice were implanted with patient tumor fragments for each operative case. The mice were monitored for tumor growth by palpation of implantation sites on a weekly basis. The time to tumor formation (TTF) was recorded when a subcutaneous nodule was palpated on the mouse's flank. Tumors were harvested when they reached a maximum diameter of 1.5 cm.
Establishment of PDX from diagnostic clinical biopsy. A patient with metastatic pancreatic adenocarcinoma underwent percutaneous ultrasonography-guided biopsy of a liver lesion by interventional radiology. The biopsy was obtained using an 18-gauge Tru-Cut Biopsy Needle (Carefusion, San Diego, CA). The biopsy fragment was immediately transferred to ice cold cell culture media. The fragment, which originally measured approximately 1.0 3 0.2 mm, was divided into 3 fragments and implanted subcutaneously into the flanks of 3 NOD/SCID mice. The mice were monitored for tumor growth by palpation of implantation sites on a weekly basis. Tumors were harvested when they reached a maximum diameter of 1.5 cm.
RESULTS
Engraftment rates. PDX engraftment rates ranged from 27.3%-70%, in the traditional method of xenograft implantation and 0%-36.4% with the biopsy method. Pancreatic and melanoma cases were the most likely to engraft, while bladder and non-small cell lung cancer (NSCLC) tumors were the least likely to engraft with the biopsy method (Table I ). The details and clinical characteristics of all attempted PDX cases are listed in Table II . Second-generation PDXs were engrafted from 2 biopsy-derived melanoma tumors. In these mice, every fragment that was implanted successfully established a tumor that histologically resembled the previous generation (data not shown).
Time to tumor formation. Xenografts derived from pancreatic adenocarcinoma specimens grew in an average time of 41 days for the traditional implantation method and 70 days for the biopsy implantation method. In melanoma specimens, traditional xenografts grew in 39 days vs 57 days for the biopsy method. In bladder cases, traditional xenografts grew in 74 days, while no biopsy xenografts grew. In NSCLC, the traditional xenografts grew in 58 days vs 60 days for the biopsy xenograft (however, only one biopsy xenograft successfully grew [ Table I] ). In all tumor types, there was a lag in tumor formation of FNAderived xenografts. However, once tumors formed, the growth rates were similar between the 2 tumors (data not shown).
Pretreatment of patient tumors has differing effects on tumor engraftment in each cancer. Our group previously showed in pancreatic ductal adenocarcinoma (PDA) xenografts that pretreated patient tumors with chemotherapy and/or radiation have lower engraftment rates than treatmentna€ ıve tumors. 9 A similar trend was observed in the pancreas specimen group of this study. Of the 10 PDA specimens, 3 were untreated; all 3 (100%) successfully engrafted via the standard approach, and two-thirds (67%) grew FNA xenografts. Seven PDA specimens were pretreated; 4 of these grew xenografts via the traditional method (57%), and only one grew an FNA xenograft (14%).
The pretreatment of melanoma, however, did not seem to affect engraftment rates. Out of the 10 In the remaining 4 pretreated specimens, 2 (50%) successfully engrafted, while none grew FNA xenografts (0%). In bladder carcinoma, 9/10 specimens were treatment na€ ıve, and 2 of these 9 (22%) grew traditional xenografts but no FNA xenografts. There was only one pretreated specimen, and it grew a traditional xenograft (100%) but not an FNA xenograft (0%). The details of each case and engraftment rates can be found in Table II .
Histology of biopsy xenografts resembles that of traditional xenografts. The histology of xenografts derived from FNAs accurately resembled the histology of human tumors and xenografts implanted with the traditional method in every case (Fig 2) , despite the biopsy xenografts starting with far fewer implanted cells. Both the traditionally implanted xenograft and the FNA xenograft resembled the histology of the original patient tumor.
Biopsy xenografts can be grown from PDA metastases. After it was shown that it was possible to grow xenograft tumors from biopsy samples of primary tumors, we then turned our attention to sampling metastatic sites of cancer patients. In one rare case, MDA-PATX113, we obtained operatively resected tumor tissue from a cervical spine metastasis from a patient with metastatic pancreatic adenocarcinoma. This sample was implanted in the same way as the previously processed primary tumors. In this case, every tumor sample that was implanted successfully grew, on both the traditional side and the FNA side of each mouse (Fig 2) .
We then sought to grow a pancreatic adenocarcinoma xenograft grown from an outpatient biopsy. This patient, MDA-PATX121, underwent percutaneous ultrasonography-guided core needle biopsy of a liver lesion of metastatic pancreatic adenocarcinoma. The original sample was a cylindrical specimen measuring approximately 5 mm in length and 1 mm in diameter. The tumor core was divided into 3 pieces and implanted into 3 NOD/ SCID mice, all of which grew palpable xenograft tumors by 57 days (Fig 3) . One important difference in this case was that the core biopsy fragments were larger and therefore contained more cells than the FNAs implanted in the other cases; however, these core needle biopsy fragments were still far smaller than the ;3 mm 3 tumor fragments that have been used in previously described methods. 4, 5 In short, the 2 pancreatic adenocarcinoma cases established from metastatic sites both engrafted successfully, and moreover, all mice that were implanted successfully grew tumors at every implantation site, whether by traditional fragment, FNA, or core needle biopsy fragment. This suggests that metastatic sites may more readily establish xenografts, but more cases are needed to confirm this finding.
DISCUSSION
The solid tumors from which xenografts were attempted in this paper are inherently heterogeneous, with cells in the same tumor having varying phenotypes and genetic characteristics. [10] [11] [12] [13] [14] [15] [16] [17] [18] The success rate of establishing a xenograft depends on presence of enough cells that are able to initiate new tumor formation. [19] [20] [21] Therefore, engraftment rates were highly variable, as many groups have reported previously. 5, 22, 23 A review by Hidalgo et al 22 reported engraftment rates ranging from 3%-90% on a variety of different methodologies and tumor types.
Even within each case, the growth of the traditional xenograft did not predict the growth of the biopsy xenograft, and vice versa. There was a diverse tumor growth success rate among all mice implanted with the same tumor. For example, each mouse in one implantation group had the possibility of growing only the traditional xenograft, only the biopsy xenograft, both, or neither (data not shown). In this regard, a limitation of our study is that the FNA method may not adequately capture tumor heterogeneity, since the FNAs were performed on the single 2 mm 3 fragment that was implanted on the contralateral flank. In future practice, pooling FNAs from different quadrants of the tumor is more likely to represent the heterogeneity of the entire tumor, which may lead to more predictable engraftment.
In terms of cell numbers, we previously demonstrated that a PDX can be established with as few as 100 purified ALDH+ cells and retain the stroma architecture of the human tumor and traditional xenograft. 19 Lee et al 24 developed a method of quantifying cell numbers from 22-gauge FNA passages of mouse xenografts and detected cell counts of >1,000 cells per aspiration. Therefore, one FNA passage through a tumor should be enough to establish a xenograft, and multiple passes may increase success rates.
It is notable that xenografts established with the FNA method resulted in the same overall tumor and stroma architecture as the patient tumor. Suetsugu et al, 25 using pancreatic adenocarcinoma PDX tumors previously established by us, showed that tumors implanted in red fluorescent protein (RFP)-expressing nude mice acquired RFPpositive stroma, including cancer-associated fibroblasts and tumor-associated macrophages.
The same phenomenon happened in further passage into green fluorescent protein-expressing nude mice, and again into cyan fluorescent protein-expressing nude mice. Each passage retained fluorescent stroma, blood vessels, and stromal cells from each generation of color, indicating that the stroma of PDX tumors is murine in nature. 25 Taken together, this supports the idea that the stromal architecture of a PDX is largely determined by the phenotype of the cancer cells in how they recruit murine stroma, and transplanting large amounts of patient stroma may not be necessary for xenograft formation.
There are several other possibilities for variable engraftment rates of xenografts. One potential issue was that we implanted both samples in the same mouse. Groups have reported endocrine effects of tumors impacting the growth of distant tumors on the same animal. 26, 27 In those studies, however, tumors were generated from different cell lines with different phenotypes, while both of our tumors were derived from a relatively similar area of a single patient's tumor.
While there could be significant intratumoral heterogeneity, we felt that the tumors were composed similarly enough as to not impact the growth of each other. The only way to assure lack of interference between multiple tumors on the same animal is to only implant one sample per mouse; however, this requires considerable extra resources. One more reason for variable engraftment rates of PDX is pretreatment of the patient's tumor with chemotherapy and/or radiation.
We have shown previously that pretreatment of a pancreatic adenocarcinoma tumor with neoadjuvant chemotherapy can decrease the engraftment rate by 40%. 9 Although we did not have large enough sample sizes for statistical analysis, this trend was recaptured in our study. Pretreatment did not seem to affect engraftment rates of the other tumors, but larger sample sizes are necessary to truly determine the effect of pretreatment on FNA xenografts.
Patient-derived tumor xenografts derived from pancreatic adenocarcinoma, melanoma, and NSCLC were more likely to form compared to urothelial carcinomas, which had lower growth rates. These differing success rates likely reflect the relative growth rates of these cancers. NSCLC and bladder cancer cases that were attempted at engraftment were collected from less advanced disease than those from pancreas and melanoma. In the case of NSCLC, this resulted in a small volume of tumor tissue being available for xenografting. Therefore, only 2-3 mice were implanted with tumor tissue, rather than 5 mice as in the pancreas, melanoma, and bladder sets.
This may have caused the success rate to be lower than what would have been possible if tumor fragments were implanted in 5 mice for each case. The high success rate of metastatic lesion engraftment suggests that more advanced disease will be more likely to form a xenograft; however, more cases are needed to confirm this observation. Therefore, a weakness of this study is the lack of cases attempted with more advanced/metastatic bladder and NSCLC cancers.
In both cases where tissue was obtained from metastases of pancreatic adenocarcinoma, MDA-PATX113 and MDA-PATX121, every FNA or core biopsy fragment that was implanted grew into a large xenograft. This adds weight to the relevance of this approach, since metastatic lesions are overall less likely to be operatively resected, leaving little chance for xenografts to ever be generated from them.
Allaway et al 8 also showed that engraftment of FNA specimens from metastatic pancreatic adenocarcinoma sites was also more successful than FNA specimens of the primary site. In the future, clinicians and researchers could consider obtaining biopsy tissue from metastatic tumor sites, since it potentially has a high chance of successfully establishing a xenograft. However, we did not examine whether this this was an effect of cell number or tumor biology of cell number versus tumor biology of primary tumors versus metastases, which is a limitation of this study and warrants further exploration. In this study, we have shown that it is possible to generate xenografts from small volumes of tumor samples that can be obtained during an outpatient FNA or core needle biopsy. This will enable tumor xenografts to be grown from patients who cannot be operative candidates. The successful growth of a PDX from operatively resected tumor predicts clinical recurrence in pancreatic adenocarcinoma, and these patients are unlikely to be operated on additional times. 28 This method potentially opens the door to xenograft research on these recurrences in order to compare them to the xenograft grown from the primary tumor.
Also, with abundant xenograft tissue, laboratories could also generate cell lines from each clinical scenario, as we have shown previously. 29 These PDX tumors and cell lines can be beneficial for future preclinical studies and also guide personalized therapy for current patients by testing different chemotherapeutics on mice bearing tumors generated from the patient's own tumor tissue. 4 The future direction for this project will be attempting xenografts of more biopsy samples from different cancers, especially metastases, obtained during outpatient diagnostic procedures rather than operative resections.
